Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 Other solid neoplasm 1

Conditions

Carcinoma, Hepatocellular 66 Carcinoma, Renal Cell 38 Liver Neoplasms 20 Neoplasm Metastasis 17 Carcinoma, Non-Small-Cell Lung 16 Neoplasms 15 Breast Neoplasms 15 Melanoma 13 Thyroid Neoplasms 10 Leukemia, Myeloid, Acute 10 Sarcoma 9 Lung Neoplasms 8 Kidney Neoplasms 8 Prostatic Neoplasms 7 Ovarian Neoplasms 7 Urinary Bladder Neoplasms 6 Pancreatic Neoplasms 6 Glioblastoma 6 Brain Neoplasms 6 Colorectal Neoplasms 5 Carcinoma, Medullary 5 Thyroid Carcinoma, Anaplastic 4 Stomach Neoplasms 4 Rectal Neoplasms 4 Gliosarcoma 4 Gallbladder Neoplasms 4 Colonic Neoplasms 4 Breast Neoplasms, Male 4 Thyroid Diseases 3 Thyroid Cancer, Papillary 3

Interventions

Pemetrexed 10 Cisplatin 9 Gemcitabine 8 Nivolumab 5 Ipilimumab 4 Carboplatin 4 niraparib 3 durvalumab 3 Vinorelbine 3 Bevacizumab 3 tremelimumab 2 pembrolizumab 2 olaparib 2 anetumab ravtansine 2 Radiotherapy, Intensity-Modulated 2 Oxaliplatin 2 Imatinib Mesylate 2 Hyperthermic Intraperitoneal Chemotherapy 2 Fluorodeoxyglucose F18 2 Cytoreduction Surgical Procedures 2 vandetanib 1 tislelizumab 1 tazemetostat 1 spartalizumab 1 sargramostim 1 ribociclib 1 fludarabine phosphate 1 fludarabine 1 dostarlimab 1 defactinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Mesothelioma × Sorafenib × Clear all

NCT00794859 2009-08-04

SMS

King's College London

Phase 2 Unknown

Other solid neoplasmThoracic

Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡